Please use this identifier to cite or link to this item:
Title: Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: a prospective study of 3057 matched case‐control sets from EPIC
Author: Schmidt, Julie A.
Fensom, Georgina K.
Rinaldi, Sabina
Scalbert, Augustin
Appleby, Paul N.
Achaintre, David
Gicquiau, Audrey
Gunter, Marc J.
Ferrari, Pietro
Kaaks, Rudolf
Kühn, Tilman
Boeing, Heiner
Trichopoulou, Antonia
Karakatsani, Anna
Peppa, Eleni
Palli, Domenico
Sieri, Sabina
Tumino, Rosario
Bueno de Mesquita, H. Bas
Agudo, Antonio
Sánchez, Maria Jose
Chirlaque, María Dolores
Ardanaz, Eva
Larrañaga, Nerea
Pérez Cornago, Aurora
Assi, Nada
Riboli, Elio
Tsilidis, Konstantinos K.
Key, Timothy J.
Travis, Ruth C.
Keywords: Càncer de pròstata
Prostate cancer
Issue Date: 29-Apr-2019
Publisher: Wiley & Sons Ltd.
Abstract: Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD ) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66-0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57-0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69-0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61-0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer.
Note: Reproducció del document publicat a:
It is part of: International Journal of Cancer, 2019, vol. 146, num. 3, p. 720-730
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
ijc.32314.pdf1.01 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons